15 Best Cheap Stocks to Buy for 2025

Page 7 of 14

8. Johnson & Johnson (NYSE:JNJ)

Forward P/E Ratio as of January 15: 13.61

Number of Hedge Fund Investors: 81

Johnson & Johnson (NYSE:JNJ) is a leading global healthcare company with a diverse portfolio spanning pharmaceuticals, medical devices, and consumer health products. The company operates in over 60 countries and sells products in more than 175 markets.

Johnson & Johnson (NYSE:JNJ) is actively shifting its portfolio and pipeline towards high-innovation and high-growth markets. The company recently completed the acquisitions of companies such as Shockwave Medical, V-Wave, and Ambrx, which have bolstered the company’s presence in the cardiovascular and oncology sectors. The acquisition of Shockwave Medical has made Johnson & Johnson (NYSE:JNJ) a category leader in four of the largest and highest-growth cardiovascular intervention markets. The company’s investment in these high-growth areas is expected to drive significant sales and revenue growth in the coming years.

Johnson & Johnson (NYSE:JNJ) has been investing heavily in R&D, with nearly $5 billion allocated in the third quarter of 2024. This investment includes significant payments for securing global rights to innovative assets such as the NM26 bispecific antibody. Additionally, the company is optimizing its operations following the separation of Kenvue, the consumer health business, which has led to improved operational efficiency and cost savings.

Page 7 of 14